Galectin Therapeutics
GALT | NASDAQ
$3.02
-$0.03 (-0.98%)
At close: Nov 16, 2026, 4:00 PM ET
$3.02
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-0.98%
(1D)No price chart data available for 1D timeframe.
Rating
31
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #763/1021 (Top 75%)
Key Statistics
Market Data
Market Cap $198.89M
1D Range
2.93 3.22
52W Range
2.08 6.51
Valuation (TTM)
PE -7.02
PB -1.45
EV/EBITDA -23.51
Valuation (NTM)
Forward PE N/A
Forward PEG 0.18
Price Target $11.00
Cash Flow
FCF Yield -8.0%
SBC Adj. FCF Yield -9.2%
SBC Impact -14.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 29.0% |
9.7%
FCF 3Y | 5Y 30.1% |
8.0%
Returns
ROA -187.8%
ROE 21.5%
ROIC -1613.8%
Financial Health
Net Debt
$124.43M
Current Ratio 0.10
Interest Coverage -2.02
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disord...
Sector Healthcare
Industry Biotechnology
Employees 9
IPO Date Sep 4, 2002
Website galectintherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$11.00
Upside
+264.24%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove GALT